Literature DB >> 18278174

Clearance of von Willebrand factor.

Cécile V Denis1, Olivier D Christophe, Beatrijs D Oortwijn, Peter J Lenting.   

Abstract

The life cycle of von Willebrand factor (VWF) comprises a number of distinct steps, ranging from the controlled expression of the VWF gene in endothelial cells and megakaryocytes to the removal of VWF from the circulation. The various aspects of VWF clearance have been the objects of intense research in the last few years, stimulated by observations that VWF clearance is a relatively common component of the pathogenesis of type 1 von Willebrand disease (VWD). Moreover, improving the survival of VWF is now considered as a viable therapeutic strategy to prolong the half-life of factor VIII in order to optimise treatment of haemophilia A. The present review aims to provide an overview of recent findings with regard to the molecular basis of VWF clearance. A number of parameters have been identified that influence VWF clearance, including its glycosylation profile and a number of VWF missense mutations. In addition, in-vivo studies have been used to identify cells that contribute to the catabolism of VWF, providing a starting point for the identification of receptors that mediate the cellular uptake of VWF. Finally, we discuss recent data describing chemically modification of VWF as an approach to prolong the half-life of the VWF/FVIII complex.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18278174     DOI: 10.1160/TH07-10-0629

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  13 in total

Review 1.  Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy.

Authors:  Ricardo J Solá; Kai Griebenow
Journal:  BioDrugs       Date:  2010-02-01       Impact factor: 5.807

Review 2.  Laboratory testing for von Willebrand disease: toward a mechanism-based classification.

Authors:  Richard Torres; Yuri Fedoriw
Journal:  Clin Lab Med       Date:  2009-06       Impact factor: 1.935

Review 3.  von Willebrand factor: at the crossroads of bleeding and thrombosis.

Authors:  Cécile V Denis; Peter J Lenting
Journal:  Int J Hematol       Date:  2012-04-05       Impact factor: 2.490

4.  Intersectin-1s: an important regulator of cellular and molecular pathways in lung injury.

Authors:  Dan N Predescu; Cristina Bardita; Rajive Tandon; Sanda A Predescu
Journal:  Pulm Circ       Date:  2013-12-05       Impact factor: 3.017

5.  Phospholipid binding improves plasma survival of factor VIII.

Authors:  Dipak S Pisal; Sathy V Balu-Iyer
Journal:  Thromb Haemost       Date:  2010-09-13       Impact factor: 5.249

6.  Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial.

Authors:  Pier Mannuccio Mannucci; Christine Kempton; Carolyn Millar; Edward Romond; Amy Shapiro; Ingvild Birschmann; Margaret V Ragni; Joan Cox Gill; Thynn Thynn Yee; Robert Klamroth; Wing-Yen Wong; Miranda Chapman; Werner Engl; Peter L Turecek; Tobias M Suiter; Bruce M Ewenstein
Journal:  Blood       Date:  2013-06-18       Impact factor: 22.113

7.  Effects of plasma glycosyltransferase on the ABO(H) blood group antigens of human von Willebrand factor.

Authors:  Taiki Kano; Kazunao Kondo; Jiharu Hamako; Fumio Matsushita; Kazuya Sakai; Taei Matsui
Journal:  Int J Hematol       Date:  2018-04-04       Impact factor: 2.490

8.  FcRn Rescues Recombinant Factor VIII Fc Fusion Protein from a VWF Independent FVIII Clearance Pathway in Mouse Hepatocytes.

Authors:  Arjan van der Flier; Zhan Liu; Siyuan Tan; Kai Chen; Douglas Drager; Tongyao Liu; Susannah Patarroyo-White; Haiyan Jiang; David R Light
Journal:  PLoS One       Date:  2015-04-23       Impact factor: 3.240

9.  Dual roles for hepatic lectin receptors in the clearance of chilled platelets.

Authors:  Viktoria Rumjantseva; Prabhjit K Grewal; Hans H Wandall; Emma C Josefsson; Anne Louise Sørensen; Göran Larson; Jamey D Marth; John H Hartwig; Karin M Hoffmeister
Journal:  Nat Med       Date:  2009-09-27       Impact factor: 53.440

10.  On the versatility of von Willebrand factor.

Authors:  Antoine Rauch; Nikolett Wohner; Olivier D Christophe; Cécile V Denis; Sophie Susen; Peter J Lenting
Journal:  Mediterr J Hematol Infect Dis       Date:  2013-07-10       Impact factor: 2.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.